Pulmonary Arterial Hypertension Market

Pulmonary Arterial Hypertension Market Outlook 2031

The Pulmonary Arterial Hypertension Market size was USD 7.63 Billion in 2022 and is likely to reach USD 12.35 Billion by 2031, expanding at a CAGR of 5.5% during 2023–2031. The growth of the market is attributed to the rising geriatric population, robust drug pipeline, increasing prevalence of Pulmonary Arterial Hypertension (PAH), and changing lifestyle.

Favorable government initiatives for orphan drugs development is anticipate to fuel the growth of pulmonary arterial hypertension market. The patient based drug development initiative focuses on patient care in the U.S. This initiative helped in understanding of disease severity, impact of the disease on patients’ lives, and available options for the treatment such as PAH.

Get Free Sample Report

This initiative also helped for increase in awareness about rare diseases present in the U.S. among people, which aided people to go through diagnosis and take correct treatment for diseases.

Acceleron Pharma, Inc., in September 2019, got FDA approval for Sotatercept as an orphan drug for PAH treatment. Sotatercept was evaluated in two trials as the PULSAR trial and the SPECTRA exploratory trial. In January 2020, the company encountered its primary and secondary key endpoints in patients with PAH. These type of innovations are projected to fuel the market of pulmonary arterial hypertension.

Changes in lifestyle includes excessive smoking habits, lack of physical activity, consumption of fast food, and excessive consumption of alcohol increases the risk of high blood pressure and hypertension. Increased blood pressure successively increases other diseases such as pulmonary arterial hypertension, stroke, and heart attacks. Moreover, detection of PAH due to its nonspecific and mild symptoms.

Pulmonary Arterial Hypertension Market Trends, Drivers, Restraints, and Opportunities

• Successful launch of innovative drugs & treatment therapies and increasing presence of PAH disease are expected to fuel the market growth.
• Encouraging government initiatives, increasing unhealthy lifestyle, and other idiopathic conditions are anticipated to boosts the market expansion over the forecast period.
• Rapid growth in acceptance of treatment and increasing spending on healthcare are factors responsible for the market growth.
• Patent expiration of drug molecule, termination of drugs by key players during clinical trials, and unawareness about presence of PAH among patients are anticipated to hamper the market expansion.
• Awareness about side effects of the drugs and high treatment and diagnosis cost are projected to impede the market growth over the forecast period.

Scope of Pulmonary Arterial Hypertension Market Report

The report on the global pulmonary arterial hypertension market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Pulmonary Arterial Hypertension Market Segment Insights

Prostacyclin & prostacyclin analogs segment is projected to hold a key market share

Based on drug classes, the pulmonary arterial hypertension market is segmented into prostacyclin & prostacyclin analogs, endothelin receptor antagonists (ERA), phosphodiesterase 5 (PDE-5), and soluble guanylate cyclase (SGC) stimulators. The prostacyclin & prostacyclin analogs segment is expected to hold a key share of the market during the forecast period due to rise in sales of drug for the treatment of PAH. The increasing use of oral prostacyclin agents includes Orenitram and Uptravi for treating pulmonary arterial hypertension.

On the other hand, the endothelin receptor antagonists (ERA) segment is anticipated to expand at a rapid pace during the forecast period. Opsumit and Tracleer target ET_B and ET_A receptors, while Volibris/Letairis targets the ET_A receptor.

North America is expected to dominate the market

Based on regions, the pulmonary arterial hypertension market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to dominate the market during the forecast period. The regional market growth can be attributed to the development of healthcare infrastructure in the U.S.

Furthermore, high diagnosis rate, favorable government initiatives, and growing awareness are increasing the demand of treatment for pulmonary arterial hypertension. Additionally, in the U.S. the Orphan Drug Act (ODA) 1983 and the Rare Disease Act 2002 has raised acceptance of novel medication for treating pulmonary arterial hypertension.

In Europe, the European Society of Cardiology and European Medicines Agency (EMA) promotes early diagnosis of pulmonary arterial hypertension. Increasing occurrence of risk factors and related diseases such as HIV rises the risk of pulmonary arterial hypertension. Besides, exposure to pollution, growing geriatric population, and lifestyle changes are estimated to fuel the rising prevalence of PAH in the region.

However, Asia Pacific is expected to exhibit a rapid growth rate in the coming years owing to rapid economic development, improving healthcare system, and large population base. Also, increasing burden of diseases such as HIV and diabetes is responsible for PAH development, which is expected to propel the regional market growth.

Get Free Sample Report

Segments

Drug Classes

• Prostacyclin & Prostacyclin Analogs
• Endothelin Receptor Antagonists (ERA)
• Phosphodiesterase 5 (PDE-5)
• Soluble Guanylate Cyclase (SGC) Stimulators

Regions

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• Johnson & Johnson Private Limited
• Gilead Sciences, Inc.
• United Therapeutics Corporation
• GlaxoSmithKline Plc.
• Pfizer, Inc.
• Bayer HealthCare
• Novartis International AG
• Dong-A ST Co., Ltd.
• Merck Sharp & Dohme Corp.
• Arena Pharmaceuticals

Competitive Landscape

Key players competing in the pulmonary arterial hypertension market include Johnson & Johnson Private Limited, Gilead Sciences, Inc., United Therapeutics Corporation, GlaxoSmithKline Plc., Pfizer, Inc., Bayer HealthCare, Novartis International AG, Dong-A ST Co., Ltd., Merck Sharp & Dohme Corp., and Arena Pharmaceuticals.

Major market players implement several business strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to enhance their market shares. For instance, as of July 2019, Remodulin launched by United Therapeutics Corporation. Remodulin medicine is used for pulmonary arterial hypertension treatment on adult patients.